somavaratan

Phase 3Small molecule

VVersartis Inc.

somavaratan is one of 63 small molecule programs targeting Growth Hormone Deficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Growth Hormone DeficiencyActive, not recruiting

GrowthActive, not recruiting

Growth Hormone DeficiencyPhase 2/Phase 3

Active, not recruiting

GrowthPhase 3

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

somavaratan

VVersartis Inc.

Phase 3

2 3

Lovenox

Sanofi

Preclinical

2 4

Zolymbus

AbbVie

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

Glucophage

2 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth Hormone Deficiency3 trials

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Terminated·VVersartis Inc.·Phase 2·NCT02719990·36 enrolled

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Terminated·VVersartis Inc.·Phase 3·NCT03145831·21 enrolled

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Terminated·VVersartis Inc.·Phase 2/3·NCT02413138·41 enrolled

Growth2 trials

Long-Acting Growth Hormone in Children Compared to Daily rhGH

Completed·VVersartis Inc.·Phase 3·NCT02339090·138 enrolled

Versartis International Trial in Adults With Long-Acting Growth Hormone

Completed·VVersartis Inc.·Phase 2·NCT02526420·36 enrolled

ART1 trial

Versartis Long-Term Safety Study of Somavaratan

Terminated·VVersartis Inc.·Phase 2/3·NCT02068521·385 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for somavaratan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — somavaratan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for somavaratan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Versartis Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVersartis Inc.

somavaratan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth Hormone Deficiency3 trials

Growth2 trials

ART1 trial

References

Drug Info

Quick Facts

Related News